An endoscopic AI diagnostic support medical device software that can detect early-stage colorectal cancer and precancerous lesions in real time during endoscopy, which was developed by the Cancer Translational Research Team (Team Leader: Ryuji Hamamoto) in collaboration with Dr. Masayoshi Yamada and Dr. Yutaka Saito of the Department of Endoscopy, National Cancer Center Hospital, has been approved as a medical device in Japan on November 30, 2020. On November 30, 2020, the endoscope AI diagnosis support medical device software that detects early stage colon cancer and precancerous lesions in real time during endoscopic examinations was approved as a medical device in Japan. In Europe, it also met the requirements for the CE mark, a standard for medical device products, on December 24, 2020.
This research was conducted in accordance with the research protocol [receipt number: Wako No. 1 29-1], which is based on the provisions of Article 3.1 of the RIKEN Code of Ethics for Research Involving Human Subjects, and the research protocol approved by the Research Ethics Review Committee of the National Cancer Center [research proposal number: 2016-496].
The research results on endoscope AI will also be introduced at the 8th AIP Open Seminar to be held on Wednesday, January 13.
[8th AIP Open Seminar] Talks by Cancer Translational Research Team
Press release by the National Cancer Center
https://www.ncc.go.jp/jp/information/pr_release/2020/20210112/index.html
[Collaborative Research Members]
National Cancer Center Hospital RIKEN Center for Advanced Intelligence Project
Masashi Yamada Yutaka Saito Shigemi Yamada Hiroko Kondo Ryuji Hamamoto
